Acetylon Pharmaceuticals Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Region:North America

Author(s):

Product Code:GDPH139206D

Download Sample Report download
Buy the Full ReportStarting from $250
Published on

April 2017

Total pages

20

Table of Content

Download Sample Report download
Buy the Full ReportStarting from $250

About the Report

About the Report

Acetylon Pharmaceuticals Inc (Acetylon) is a pharmaceutical company that discovers and develops next-generation selective small molecule histone deacetylase inhibitors and selective small molecule drugs. The company treat patients suffering from critical and unmet medical needs. It offers products for the treatment of cancers, including multiple myeloma, neurodegenerative, inflammatory, metabolic, and genetic and infectious parasitic diseases. Acetylon also provides clinical trials, higher dosing, extended administration, reduction of combination drug toxicity, enhanced therapeutic benefit services, and medical research and development services. The company's therapeutic areas include Ricolinostat and ACY-241 in other cancers and non-oncology indications. Acetylon is headquartered in Boston, Massachusetts, the US.

Acetylon Pharmaceuticals Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Products

Table of Contents

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Acetylon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Acetylon Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Acetylon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Acetylon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

Acetylon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9

Acetylon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

Acetylon Pharmaceuticals Secures USD100 Million in Fundnig from Celgene 10

Acetylon Pharma Raises US$15 Million From Celgene 10

Acetylon Pharma Raises Additional US$15.2 Million In Series B Financing 12

Partnerships 13

Hereditary Neuropathy Foundation Partners with Acetylon Pharma 13

Acetylon Pharma Enters Into Co-Development Agreement With Leukemia & Lymphoma Society 13

Licensing Agreements 14

Regenacy Pharma Receives Rights to HDAC6 Inhibitor, Ricolinostat ACY-1215 from Acetylon Pharma 14

Acquisition 15

Celgene to Acquire Acetylon Pharma 15

Acetylon Pharmaceuticals Inc-Key Competitors 17

Key Employees 18

Locations And Subsidiaries 19

Head Office 19

Appendix 20

Methodology 20

About GlobalData 20

Contact Us 20

Disclaimer 20


List of Figure

List of Figures

Acetylon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Acetylon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Acetylon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Acetylon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Acetylon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Acetylon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6

Acetylon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Acetylon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8


List of Table

List of Tables

Acetylon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 1

Acetylon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Acetylon Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Acetylon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Acetylon Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8

Acetylon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9

Acetylon Pharmaceuticals Secures USD100 Million in Fundnig from Celgene 10

Acetylon Pharma Raises US$15 Million From Celgene 10

Acetylon Pharma Raises Additional US$15.2 Million In Series B Financing 12

Hereditary Neuropathy Foundation Partners with Acetylon Pharma 13

Acetylon Pharma Enters Into Co-Development Agreement With Leukemia & Lymphoma Society 13

Regenacy Pharma Receives Rights to HDAC6 Inhibitor, Ricolinostat ACY-1215 from Acetylon Pharma 14

Celgene to Acquire Acetylon Pharma 15

Acetylon Pharmaceuticals Inc, Key Competitors 17

Acetylon Pharmaceuticals Inc, Key Employees 18

You can also purchase parts of this report.
Do you want to check out a section wise price list?
Get Price Break-up

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022